Mbx biosciences reports first quarter 2025 financial results and recent corporate highlights

Topline results for the phase 2 avail™ evaluating canvuparatide in patients with hypoparathyroidism expected in 3q 2025 investigational new drug submission for mbx 4291 on track for 2q 2025 $240.8 million in cash, cash equivalents and marketable securities as of march 31, 2025; expected to support operations into mid-2027 carmel, ind., may 12, 2025 (globe newswire) -- mbx biosciences, inc. (nasdaq: mbx), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the first quarter ended march 31, 2025, and highlighted recent corporate progress.
MBX Ratings Summary
MBX Quant Ranking